The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Tari King appointed chief surgical officer for cancer service line, co-director of Glenn Family Breast Center at Winship, chief of Division of Breast Surgery at Emory

Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account